A Population-Based Study of Morbidity After Pancreatic Cancer Diagnosis

Reith R. Sarkar, BS*; Katherine E. Fero, MD, MAS*; Daniel M. Seible, MD; Neil Panjwani, MD; Rayna K. Matsuno, PhD; and James D. Murphy, MD, MS

ABSTRACT

Background: Pancreatic cancer is an aggressive disease characterized by early and relentless tumor spread, thus leading healthcare providers to consider it a “distant disease.” However, local pancreatic tumor progression can lead to substantial morbidity. This study defines the long-term morbidity from local and nonlocal disease progression in a large population-based cohort. **Methods:** A total of 21,500 Medicare beneficiaries diagnosed with pancreatic cancer in 2000 through 2011 were identified. Hospitalizations were attributed to complications of either local disease (eg, biliary disorder, upper gastrointestinal ulcer/bleed, pain, pancreas-related, radiation toxicity) or nonlocal/distant disease (eg, thromboembolic events, cytopenia, dehydration, nausea/vomiting/motility problem, malnutrition and cachexia, ascites, pathologic fracture, and chemotherapy-related toxicity). Competing risk analyses were used to identify predictors of hospitalization. **Results:** Of the total cohort, 9,347 patients (43.5%) were hospitalized for a local complication and 13,101 patients (60.9%) for a nonlocal complication. After adjusting for the competing risk of death, the 12-month cumulative incidence of hospitalization from local complications was highest in patients with unresectable disease (53.1%), followed by resectable (39.5%) and metastatic disease (33.7%) at diagnosis. For nonlocal complications, the 12-month cumulative incidence was highest in patients with metastatic disease (57.0%), followed by unresectable (56.8%) and resectable disease (42.8%) at diagnosis. Multivariable analysis demonstrated several predictors of hospitalization for local and nonlocal complications, including age, race/ethnicity, location of residence, disease stage, tumor size, and diagnosis year. Radiation and chemotherapy had minimal impact on the risk of hospitalization. **Conclusions:** Despite the widely known predilection of nonlocal/distant disease spread in pancreatic cancer, local tumor progression also leads to substantial morbidity and frequent hospitalization.

J Natl Compr Canc Netw 2019;17(5):432–440
doi: 10.6004/jnccn.2018.7111

Background

Pancreatic cancer represents the fourth leading cause of cancer-related death, and the 5-year survival for all stages together ranges from 5% to 10%. Although “distant disease” spread represents the hallmark of pancreatic cancer, local tumor progression can lead to substantial patient morbidity. Recent data suggest that nearly 1 in 3 patients with pancreatic cancer will die of local disease progression.¹ In addition, cancer progression within the pancreas can cause intractable pain, gastrointestinal ulceration and bleeding, biliary obstruction, or pancreatitis.

Existing research documenting patterns of disease spread typically uses radiographic progression to define local or nonlocal/distant tumor progression.² However, radiographic progression—often defined as tumor diameter increasing by 30%—may not correlate with meaningful clinical outcomes, such as patient quality of life. Understanding the clinically meaningful patterns of disease spread will help inform providers and patients about patient-oriented consequences associated with pancreatic cancer. The purpose of this study was to characterize disease progression by evaluating patterns of hospitalization in a large cohort of patients with pancreatic cancer.

Methods

Data

A population-based retrospective cohort study was conducted using the SEER-Medicare linked database. The SEER database contains demographic and clinical data pooled from individual population-based cancer registries covering approximately 30% of the US population. Medicare provides federally funded health insurance, including inpatient and outpatient services, for individuals aged ≥ 65 years in the United States. The SEER-Medicare linkage includes Medicare claims data for patients within SEER, and claims extend from prior to diagnosis through death, which allows for assessment of patterns of care and hospitalizations over the entire course of a patient's disease.

See JNCCN.org for supplemental online content.

Department of Radiation Medicine and Applied Sciences, UC San Diego Moores Cancer Center, La Jolla, California.

*These authors contributed equally and are co-first authors.

Study Population

A total of 32,475 patients aged ≥ 66 years diagnosed with histologically confirmed malignant adenocarcinoma of the pancreas in 2000 through 2011 were identified (supplemental eTable 1, available with this article at JNCCN.org). Our analysis was restricted to those aged ≥ 66 years at diagnosis to allow a full year of claims data from which to calculate a comorbidity score. We excluded 338 patients with prior malignancies or with pancreatic cancer diagnosed at autopsy or on the death certificate alone. Another 10,637 patients with incomplete data were excluded, including those without continuous Medicare coverage (Parts A and B) or with any Part C coverage (HMO enrollment) from 12 months prior to diagnosis through time of death or last follow-up. The final study cohort comprised 21,500 patients.

Study Variables

Demographic and tumor-related information, such as patient age and cancer stage at diagnosis, year of diagnosis, sex, race, marital status, histologic grade, tumor location, and tumor size were extracted from SEER. Patients were grouped into geographic region based on location of their SEER registry: West (San Francisco, San Jose, Los Angeles, and Greater California; Seattle, Washington; New Mexico; Utah; Hawaii), Midwest (Detroit, Michigan; Iowa), South (Atlanta, rural, and greater Georgia; Kentucky; Louisiana), and East (New Jersey; Connecticut). Socioeconomic status was assessed with median regional household income as measured from 2000 census tract data. Inpatient and outpatient Medicare claims from the year before diagnosis were used to assess preexisting comorbidity using the Deyo adaptation of the Charlson comorbidity index.³ Care at a teaching hospital was defined as any indirect medical education payment noted during a hospitalization after the patient's cancer diagnosis.⁴

Treatment variables, including chemotherapy, surgery, and radiotherapy (RT), were identified from Medicare claims data. Administration of chemotherapy was determined through Medicare billing claims, including ICD-9 diagnosis and procedure codes and Healthcare Common Procedure Coding System (HCPCS) codes, using previously described methods (supplemental eTable 1).⁵ RT was identified from claims related to its planning and delivery,⁶ and a course of RT was defined as a cluster of radiation-related Medicare claims. Radiation is delivered in daily fractions, and for this study we assumed that each daily claim of a radiation treatment represented a single fraction. We further assumed that any break in RT of >30 days represented a separate course of treatment. In patients who received multiple courses of RT, we included only the first course in the analysis. Pancreatic surgery

included partial, distal, or total pancreatectomy and a pancreaticoduodenectomy (Whipple procedure) (supplemental eTable 1).

Patient Groups

Compared with categorizing patients by classic AJCC staging, we categorized them into functional groups based on stage and operability: resectable, unresectable, or metastatic. This approach is consistent with both NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pancreatic Adenocarcinoma⁷ and other studies.⁸ Patients who presented with stage IV disease at diagnosis composed the metastatic group; those with stage I–III disease at presentation who underwent cancer-directed surgery were included in the resectable group; and the remaining patients with stage I–III disease at presentation were placed into the unresectable group. The unresectable group likely included a mix of patients with technically unresectable disease and those with potentially resectable disease who did not undergo surgery due to medical comorbidity or patient choice. SEER does not include data to assess resectability and lacks information about patient preferences, so we were unable to further categorize this unresectable group.

Study End Points

The primary end point was hospitalization after pancreatic cancer diagnosis. All hospitalizations were identified from the inpatient Medicare Provider Analysis and Review (MedPAR) file and further categorized by the ICD-9 diagnosis codes during that hospitalization. We first categorized hospitalizations as either cancer-related or non-cancer-related. Among the cancer-related hospitalizations, these were further classified as due to either local disease progression or nonlocal/distant disease. Hospitalizations for local disease progression included those due to duodenal or gastric ulceration, upper gastrointestinal bleed, disorders of the biliary tree (eg, biliary obstruction, cholangitis), local pain (eg, postoperative, abdominal), problems of the pancreas itself (eg, pancreatitis), and radiation toxicity. Hospitalizations for nonlocal/distant disease included those due to thromboembolic events, cytopenia, dehydration, nausea or vomiting, malnutrition and cachexia, ascites, pathologic fracture, and chemotherapy toxicity. Complications were selected from the NCCN Guidelines for Pancreatic Adenocarcinoma.⁷ Readmissions were included, but the initial hospitalization for pancreas-directed surgery was not.

Statistical Analysis

To describe the long-term rates of hospitalization, we used competing risk models to account for the competing risk of death,⁹ which included unadjusted cumulative incidence analyses with differences between

groups assessed with Gray's test for inequality. Multivariable Fine-Gray regression models were used to identify independent predictors of hospitalization while controlling for potential confounding factors. Covariables included in the multivariable models were defined a priori and included age at diagnosis, marital status, race/ethnicity, residence in a metropolitan area, geographic region, treatment at a teaching hospital, median income, Charlson comorbidity index, disease group (resectable, unresectable, metastatic), tumor location and size, histologic grade, year of diagnosis, and sex. Because chemotherapy and RT are often delivered after diagnosis, to account for the immortal time bias we modeled receipt of these treatments as time-dependent covariables.^{10,11} All statistical tests were 2-sided, and $P < .05$ was considered significant. Analyses were conducted using SAS 9.4 (SAS Institute Inc).

Results

Cohort Characteristics

Of the 21,500 patients in the study cohort, 11,298 (52.5%) presented with metastatic disease, 3,092 (14.4%) were in

the resectable group, and 7,110 (33.1%) were in the unresectable group. Complete demographic and clinical characteristics are presented in Table 1.

Incidence of Hospitalization

Overall, 43.5% of patients (n=9,347) required hospitalization for at least one local complication and 60.9% (n=13,101) required hospitalization for at least one nonlocal complication. Among patients who were hospitalized for a complication of local disease progression, 50.6% were hospitalized more than once and 13.6% were hospitalized >3 times. The median length of hospitalization was 6 days (interquartile range, 3–10 days).

Among all patients, the 2-month incidence of hospitalization was 32.8% for local and 35.7% for nonlocal complications (Figure 1), and the 12-month incidence of hospitalization was 40.9% for local and 54.9% for nonlocal complications. The most common causes of hospitalization from local progression were biliary disorders and pancreas-related (Table 2). The most common causes of hospitalization from non-local progression were cytopenia and malnutrition/cachexia (Table 2). Supplemental eTable 2 presents

Table 1. Patient Demographic and Clinical Characteristics

Characteristic	Total Cohort, %	Resectable, %	Unresectable, %	Metastatic, %	P Value
N	21,500	3,092 (14.4%)	7,110 (33.1%)	11,298 (52.5%)	
Age at diagnosis, y					<.001
66–69	18.3	23.9	14.0	19.5	
70–74	25.2	29.6	21.8	26.2	
75–79	25.6	28.0	24.3	25.7	
≥80	30.9	18.6	39.9	28.6	
Sex					<.001
Female	54.8	55.3	57.3	53.2	
Male	45.2	44.7	42.7	46.8	
Race					<.001
White	82.0	86.1	81.0	81.5	
Hispanic	2.0	1.4	2.3	2.0	
Black	10.1	6.5	10.2	11.1	
Other	5.9	6.0	6.5	5.5	
Marital status					<.001
Married	53.3	60.4	48.7	54.3	
Unmarried	46.7	39.6	51.3	45.7	
Geographic region					<.001
West	40.1	39.0	42.2	39.1	
Midwest	13.5	11.9	12.9	14.3	
South	22.9	23.9	22.5	22.9	
East	23.5	25.2	22.4	23.7	

(continued on next page)

Table 1. Patient Demographic and Clinical Characteristics (cont.)

Characteristic	Total Cohort, %	Resectable, %	Unresectable, %	Metastatic, %	P Value
Area of residence					.005
Metropolitan	84.6	85.6	83.5	85.0	
Other	15.4	14.4	16.5	15.0	
Median income					<.001
Bottom quartile	24.3	19.9	25.7	24.6	
2nd quartile	23.4	22.5	24.4	23.0	
3rd quartile	24.5	24.6	24.4	24.6	
Top quartile	27.8	33.1	25.6	27.8	
Teaching hospital					<.001
No	43.7	19.2	46.2	48.8	
Yes	56.3	80.8	53.8	51.2	
Pancreas site					<.001
Body/Tail	22.1	13.2	12.3	30.6	
Head	51.3	75.4	64.6	36.3	
Other	26.7	11.4	23.1	33.1	
Tumor size, cm					<.001
<2	7.3	17.3	6.7	4.9	
2–5	46.5	67.2	48.9	39.3	
>5	26.8	12.4	25.1	31.8	
Unknown	19.5	3.0	19.3	24.1	
Charlson comorbidity index					<.001
0	48.3	51.8	46.3	48.6	
1	28.1	30.0	27.8	27.8	
2	12.6	10.5	13.1	12.9	
≥3	10.9	7.6	12.8	10.7	
Radiotherapy, yes	17.7	40.9	25.0	6.8	<.001
Chemotherapy, yes	41.4	61.9	38.7	37.5	<.001

causes of hospitalization stratified by receipt of RT and chemotherapy.

Causes of Hospitalization by Patient Group

Risk of hospitalization varied by disease stage at presentation (Figure 2). Patients from the resectable and unresectable groups tended to be hospitalized because of local complications early in their clinical course, although over time the risk of hospitalization from nonlocal complications surpassed that from local complications. The 12-month cumulative incidence of local complications was highest for patients from the unresectable group (53.1%), followed by the resectable group (39.5%), and lowest for the metastatic group (33.7%). The 12-month cumulative incidence of nonlocal complications was highest for patients from the metastatic group (57.0%), followed by those from the unresectable (56.8%) and resectable groups (42.8%) (Table 2).

Predictors of Complications Requiring Hospitalization

On multivariable analysis identifying predictors of hospitalization, compared with patients with metastatic

Figure 1. Cumulative incidence of hospitalization after diagnosis caused by local complication (light blue line) and nonlocal complication (dark blue line).

Table 2. Twelve-Month Cumulative Incidence of Local and Nonlocal Complications Requiring Hospitalization^a

Complication	12-Month Cumulative Incidence, %			
	All Patients (N=21,500)	Resectable (N=3,092)	Unresectable (N=7,110)	Metastatic (N=11,298)
Local				
Biliary disorder	30.4	29.4	43.2	22.6
Upper gastrointestinal ulcer/bleed	5.7	4.3	7.8	4.7
Pain	6.0	5.7	5.6	6.2
Pancreas-related	11.3	14.2	15.1	8.2
Radiation toxicity	0.2	0.5	0.4	0.1
Local composite	40.9	39.5	53.1	33.7
Nonlocal/Distant				
DVT/PE	6.6	5.3	4.7	8.1
Cytopenia	30.1	25.9	32.8	29.6
Dehydration	13.5	13.4	14.0	13.2
Nausea/Vomiting/Motility problem	20.8	20.8	23.0	19.4
Malnutrition and cachexia	23.0	20.5	24.7	22.7
Ascites	5.9	4.0	4.4	7.4
Pathologic fracture	0.8	0.6	0.5	1.0
Chemotherapy-related toxicity	0.7	0.7	0.9	0.7
Nonlocal composite	54.9	42.8	56.8	57.0

Abbreviation: DVT/PE, deep vein thrombosis/pulmonary embolism.

^aEach patient may have presented with >1 symptom.

disease, those with unresectable disease were at a 49% increased risk of hospitalization for local complications (subdistribution hazard ratio [SDHR], 1.49; 95% CI, 1.43–1.57), whereas those with resectable disease were at a 13% decreased risk (SDHR, 0.87; 95% CI, 0.81–0.94) (Figure 3). Other factors that increased risk of hospitalization for local complications included younger age, Hispanic ethnicity, living in the Midwest, care at a teaching hospital, higher comorbidity, smaller tumor size, and tumor in the head of the pancreas. Neither chemotherapy nor RT were associated with a significant decrease in the risk of local complications.

When considering predictors of hospitalization for nonlocal disease, we found that patients with resectable disease had a 32% decreased risk of hospitalization compared with those with metastatic disease (SDHR, 0.68; 95% CI, 0.65–0.72). There was no difference in the risk of hospitalization for a nonlocal complication between the unresectable and metastatic groups (SDHR, 0.96; 95% CI, 0.92–1.00) (Figure 3). Other factors that increased the risk of hospitalization for complications of nonlocal disease included younger age, black race, living in a metropolitan area, living in the Midwest, care at a teaching hospital, lower income (bottom quartile), higher comorbidity, larger tumor size, and tumor in the head of the pancreas (Figure 3).

Neither chemotherapy nor RT were associated with a significant decrease in the risk of nonlocal complications (Figure 3).

Discussion

This population-based study is likely the first to define the specific patterns and causes of hospitalization for a large real-life cohort of elderly patients with pancreatic cancer. The key finding of this study is the high observed rates of hospitalization for both local and nonlocal disease progression. Pancreatic cancer represents an aggressive lethal cancer characterized by early and aggressive tumor spread. Most patients have overt metastatic or micrometastatic disease on presentation, which leads researchers and clinicians to often consider pancreatic cancer a problem of “distant” metastatic disease. Improving outcomes among this challenging disease will certainly require novel advances in systemic therapy; however, the findings of our study highlight the clinical importance of considering both the local pancreatic tumor and nonlocal/distant metastatic disease in optimizing patient care.

Our findings complement other research that demonstrates the clinical importance of local pancreatic tumor progression. A group from Johns Hopkins performed autopsies on 76 patients with pancreatic cancer and

Figure 2. Cumulative incidence of hospitalization after diagnosis by patients with (A) resectable, (B) unresectable, and (C) metastatic disease.

found that 30% died of local tumor destruction.¹ Furthermore, a single-center study from our institution found that the risk of hospitalization from complications of the local tumor was 45%.¹² Local tumor progression can lead to pain, biliary obstruction, and gastric ulcers and bleeding, all of which reduce patient quality of life. Although RT has the capacity to improve local tumor control and reduce complications from local tumor progression, randomized clinical trials have produced mixed survival results for patients with pancreatic cancer treated with RT.^{13,14} Furthermore, the absolute local control benefit of using conventionally fractionated radiation seems to be small. The randomized LAP07 trial¹³ found that chemoradiotherapy among patients with locally advanced pancreatic cancer decreased the risk of local tumor progression by 14%. Similarly, our study found that RT did not significantly reduce the risk of hospitalization from local tumor progression. Although alternative radiation strategies

such as stereotactic body RT¹⁵ and dose-escalated RT¹⁶ hold promise, researchers lack randomized evidence supporting widespread use. Optimizing patient quality of life requires improved strategies to mitigate the complications from local tumor progression. These strategies could include ablative local therapies, such as cryotherapy¹⁷; irreversible electroporation¹⁸; or palliative measures, such as biliary stenting/bypass¹⁹ and celiac plexus block.²⁰ Another possible intervention includes monitoring patient-reported outcomes, which in select populations of patients with cancer may reduce the risk of hospitalization²¹ and improve survival.²² Finally, an option that should be explored is early integration of palliative care, which has been shown to relieve symptoms, reduce hospitalizations, and improve survival in metastatic non-small cell lung cancer.²³ Given the high cost of hospitalizations,²⁴ improvements in locally directed palliative interventions may reduce the overall economic impact of pancreatic cancer. In general, research efforts in pancreatic cancer most often strive to improve survival, although the impact of treatment on long-term quality of life and cost of care must also be considered.

This study builds on a prior study by Reddy et al²⁵ of 1,730 Medicare beneficiaries with resectable pancreatic cancer who underwent pancreatectomy. In this study, which resulted in a readmission rate of 53% at 1 year, 25% of readmissions likely arose from operative complications and 48% were potentially associated with recurrence. Our study sought to define risk factors for hospitalization to help better risk-stratify patients (Figure 3). With hospitalization due to local tumor progression, we found the highest risk among patients with unresectable disease, and for hospitalization from nonlocal disease spread, the highest risk was among those with metastatic disease. We also found that younger patients had a higher risk of hospitalization. Recent studies have shown that younger patients have longer overall survival,^{26,27} raising the question of whether disease biology may differ by patient age.

In addition, we found that the risk of hospitalization was higher in nonwhite patients, which could reflect known health disparities that influence patterns of care,^{28,29} and that the risk of hospitalization varied by geography. Other research has documented variability in hospitalization rates by geographic region, which may reflect regional differences in patient behavior, referral patterns, or treatment options offered to patients.^{24,30}

In this study, receiving care at a teaching hospital was associated with a significantly increased risk of both local and nonlocal hospitalization. These data lack the granularity to determine the etiology of the link between academic teaching hospitals and hospitalizations. However, this observation could arise due to underlying

Figure 3. Results of multivariable Fine-Gray regression model. This forest plot depicts results of the multivariable competing risk analysis used to identify predictors of hospitalization caused by local and nonlocal causes. SDHRs >1 reflect increased risk of hospitalization and SDHRs <1 reflect decreased risk of hospitalization. An SDHR of 1.0 means that there was no increased risk of hospitalization.

Abbreviation: SDHR, subdistribution hazard ratio.

differences in patient complexity or difference in institutional treatment patterns.^{31,32}

One unexpected finding was the observed association between larger primary tumor size on presentation and paradoxically lower rates of hospitalization caused by local complications. The underlying explanation of this association is unknown; however, it could reflect differences in presentation. Perhaps patients who present with larger primaries have tumors anatomically located in regions that elicit fewer symptoms and have a decreased likelihood of leading to hospitalization. Overall, understanding these associations could help clinicians better identify patients at a higher risk of hospitalization from pancreatic cancer.

Limitations of this study largely arise from those surrounding the data within the SEER-Medicare linked database, which lack specific details of patient characteristics, performance status, metastatic disease burden, and treatment, all of which very likely influence a patient's risk of hospitalization. Another limitation is an inability to account for complications managed on an outpatient basis or in an emergency department, including pain, lethargy, nausea, and dysphagia, all of which contribute substantially to pancreatic cancer morbidity but may not be severe enough to warrant an inpatient admission.³³ Along these lines, we suspect that the number of emergency department visits is higher than the number of hospitalizations. In addition, we determined the cause of hospitalization through billing codes, which raises the possibility of misclassification of this study's primary outcome. Unmeasured confounding factors, such as patient anatomy and performance status, could also impact these study results. Furthermore, distinguishing whether complications arise from local or nonlocal disease can pose a challenge in

retrospectively collected data, particularly when using billing claim data as a proxy for patient complications. For example, biliary obstruction could arise from the primary tumor obstructing bile flow (local) or from a metastatic tumor in the hilum of the liver causing bile obstruction. Although one would expect most biliary obstruction cases in this study to arise from local tumor progression, misclassification remains a possibility. Despite these limitations, this study offers useful insight into the morbidity that patients experience with pancreatic cancer.

Conclusions

Combating metastatic disease represents a key therapeutic goal in the overall management of pancreatic cancer, although this study demonstrates the clinical importance of considering the local tumor and nonlocal disease in the overall management of patients with pancreatic cancer.

Submitted April 5, 2018; accepted for publication December 10, 2018.

Previous publication: This study was published as an abstract in *J Clin Oncol* 2018;36(Suppl 4):Abstract 236.

Author contributions: Study concept: Sarkar, Fero, Murphy. Data curation: All authors. Formal analysis: Sarkar, Fero, Seible, Panjwani, Murphy. Software: Sarkar, Fero, Matsuno, Murphy. Investigation: Sarkar, Fero, Seible, Murphy. Methodology: All authors. Validation: Sarkar, Fero, Panjwani, Murphy. Visualization: Sarkar, Fero, Matsuno. Supervision: Fero, Seible, Murphy. Resources: Murphy. Writing—original draft: Sarkar, Fero, Murphy. Writing—review and editing: Sarkar, Seible, Panjwani, Murphy.

Disclosures: The authors have not received any financial consideration from any person or organization to support the preparation, analysis, results, or discussion of this article.

Correspondence: James D. Murphy, MD, MS, Department of Radiation Medicine and Applied Sciences, UC San Diego Moores Cancer Center, 3855 Health Sciences Drive, Suite 1414, La Jolla, CA 92093-0843. Email: j2murphy@ucsd.edu

References

1. Iacobuzio-Donahue CA, Fu B, Yachida S, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. *J Clin Oncol* 2009;27:1806–1813.
2. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer* 2009;45:228–247.
3. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. *J Clin Epidemiol* 1992;45:613–619.
4. Simpson DR, Martínez ME, Gupta S, et al. Racial disparity in consultation, treatment, and the impact on survival in metastatic colorectal cancer. *J Natl Cancer Inst* 2013;105:1814–1820.
5. Warren JL, Harlan LC, Fahey A, et al. Utility of the SEER-Medicare data to identify chemotherapy use. *Med Care* 2002;40(Suppl 8):IV-55–61.
6. Virnig BA, Warren JL, Cooper GS, et al. Studying radiation therapy using SEER-Medicare-linked data. *Med Care* 2002;40(Suppl 8):IV-49–54.
7. Tempero MA, Malafa MP, Al-Hawary M, et al. NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma. Version 2.2018. Accessed August 14, 2018. To view the most recent version of these guidelines, visit NCCN.org.
8. O'Neill CB, Atoria CL, O'Reilly EM, et al. Costs and trends in pancreatic cancer treatment. *Cancer* 2012;118:5132–5139.
9. Fine J, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. *J Am Stat Assoc* 1999;94:496–509.
10. Shintani AK, Girard TD, Eden SK, et al. Immortal time bias in critical care research: application of time-varying Cox regression for observational cohort studies. *Crit Care Med* 2009;37:2939–2945.
11. Zhang Z. Survival analysis in the presence of competing risks. *Ann Transl Med* 2017;5:47.
12. Fero KE, Seible DM, Cardillo N, et al. Natural progression of symptoms after diagnosis of pancreatic cancer [abstract]. *J Clin Oncol* 2016;34(Suppl):Abstract e15748.
13. Hammel P, Huguet F, van Laethem JL, et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. *JAMA* 2016;315:1844–1853.
14. Loehrer PJ Sr, Feng Y, Cardenes H, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. *J Clin Oncol* 2011;29:4105–4112.
15. Herman JM, Chang DT, Goodman KA, et al. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. *Cancer* 2015;121:1128–1137.

16. Krishnan S, Chadha AS, Suh Y, et al. Focal radiation therapy dose escalation improves overall survival in locally advanced pancreatic cancer patients receiving induction chemotherapy and consolidative chemoradiation. *Int J Radiat Oncol Biol Phys* 2016;94:755–765.
17. Luo XM, Niu LZ, Chen JB, et al. Advances in cryoablation for pancreatic cancer. *World J Gastroenterol* 2016;22:790–800.
18. Martin RC II. Irreversible electroporation of locally advanced pancreatic neck/body adenocarcinoma. *J Gastrointest Oncol* 2015;6:329–335.
19. Boulay BR, Parepally M. Managing malignant biliary obstruction in pancreas cancer: choosing the appropriate strategy. *World J Gastroenterol* 2014;20:9345–9353.
20. Wong GY, Schroeder DR, Carns PE, et al. Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized controlled trial. *JAMA* 2004;291:1092–1099.
21. Basch E, Deal AM, Kris MG, et al. Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. *J Clin Oncol* 2016;34:557–565.
22. Basch E, Deal AM, Dueck AC, et al. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. *JAMA* 2017;318:197–198.
23. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. *N Engl J Med* 2010;363:733–742.
24. Wang Y, Schrag D, Brooks GA, et al. National trends in pancreatic cancer outcomes and pattern of care among Medicare beneficiaries, 2000 through 2010. *Cancer* 2014;120:1050–1058.
25. Reddy DM, Townsend CM, Kuo YF, et al. Readmission after pancreatectomy for pancreatic cancer in Medicare patients. *J Gastrointest Surg* 2009; 13:1963–1974, discussion 1974–1975.
26. He J, Edil BH, Cameron JL, et al. Young patients undergoing resection of pancreatic cancer fare better than their older counterparts. *J Gastrointest Surg* 2013;17:339–344.
27. Sehgal R, Alsharedi M, Larck C, et al. Pancreatic cancer survival in elderly patients treated with chemotherapy. *Pancreas* 2014;43:306–310.
28. Wray CJ, Castro-Echeverry E, Silberfein EJ, et al. A multi-institutional study of pancreatic cancer in Harris County, Texas: race predicts treatment and survival. *Ann Surg Oncol* 2012;19:2776–2781.
29. Singal V, Singal AK, Kuo YF. Racial disparities in treatment for pancreatic cancer and impact on survival: a population-based analysis. *J Cancer Res Clin Oncol* 2012;138:715–722.
30. Guadagnolo BA, Liu CC, Cormier JN, et al. Evaluation of trends in the use of intensity-modulated radiotherapy for head and neck cancer from 2000 through 2005: socioeconomic disparity and geographic variation in a large population-based cohort. *Cancer* 2010;116:3505–3512.
31. Bakens MJ, van Gestel YR, Bongers M, et al. Hospital of diagnosis and likelihood of surgical treatment for pancreatic cancer. *Br J Surg* 2015;102:1670–1675.
32. Youngwirth LM, Nussbaum DP, Thomas S, et al. Nationwide trends and outcomes associated with neoadjuvant therapy in pancreatic cancer: an analysis of 18,243 patients. *J Surg Oncol* 2017;116:127–132.
33. Keane MG, Horsfall L, Rait G, et al. A case-control study comparing the incidence of early symptoms in pancreatic and biliary tract cancer. *BMJ Open* 2014;4:e005720.

See JNCCN.org for supplemental online content.

Supplemental online content for:

A Population-Based Study of Morbidity After Pancreatic Cancer Diagnosis

Reith R. Sarkar, BS; Katherine E. Fero, MD, MAS; Daniel M. Seible, MD; Neil Panjwani, MD;
Rayna K. Matsuno, PhD; and James D. Murphy, MD, MS

J Natl Compr Canc Netw 2019;17(5):432–440

eTable 1: ICD-9 and HCPCS Codes Utilized for Diagnosis and Treatment

eTable 2: Twelve-Month Cumulative Incidence of Local and Nonlocal Complications Requiring Hospitalization,
Stratified by Radiotherapy or Chemotherapy

eTable 1. ICD-9 and HCPCS Codes Utilized for Diagnosis and Treatment

SEER Variable		SEER Code		
Pancreatic cancer		8000, 8010, 8020, 8021, 8022, 8141, 8140, 8211, 8230, 8500, 8521, 8050, 8453, 8470, 8471, 8472, 8473, 8481, 8503		
Medicare Variable		ICD-9 Diagnosis Code	ICD-9 Procedure Code	HCPCS Codes
Treatment variables	Chemotherapy	V581, V5811, V5812, V662, V672	9925	G0345, G0346, G0347, G0348, G0349, G0350, G0351, G0353, G0354, G0355, G0356, G0357, G0358, G0359, G0360, G0361, G0362, G0363, G9021, G9022, G9023, G9024, G9025, G9026, G9027, G9028, G9029, G9030, G9031, G9032, J9000–J9999, J8520–J8999, Q0083, Q0084, Q0085, 96400–96499, 96500–96599
	Radiotherapy (including simulation, planning, daily treatments, and weekly management)			61793, 61796, 61797, 61798, 61799, 61800, 63620, 63621, 76370, 77014, 77261, 77262, 77263, 77280, 77285, 77290, 77295, 77299, 77300, 77301, 77305, 77310, 77315, 77321, 77326, 77327, 77328, 77331, 77332, 77333, 77334, 77336, 77338, 77370, 77371, 77372, 77373, 77399, 77401, 77402, 77403, 77404, 77405, 77406, 77407, 77408, 77409, 77410, 77411, 77412, 77413, 77414, 77415, 77416, 77417, 77418, 77419, 77420, 77421, 77422, 77423, 77425, 77427, 77430, 77431, 77432, 77435, 77470, 77499, 77520, 77522, 77523, 77525, 77761, 77762, 77763, 77776, 77777, 77778, 77781, 77782, 77783, 77784, 77785, 77786, 77787, 77789, 77790, 77799, 0082T, 0083T, 0190T, 0197T, G0173, G0174, G0178, G0242, G0243, G0251, G0256, G0261, G0338, G0339, G0340
	Surgical resection		52.5, 52.51, 52.52, 52.53, 52.59, 52.6, 52.7	48140, 48145, 48146, 48150, 48152, 48153, 48154, 48155, 48160
Local complications	Biliary	5750, 57510, 57511, 57512, 5761, 5762, 5763, 5764, 5768, 5769, 7824		
	Pain-related	33818, 33819, 33828, 33829, 3383, 3384, 78900, 78901, 78902, 78903, 78904, 78905, 78906, 78907, 78909		
	Pancreas-related	5770, 5771, 5778, 5779		
	Upper gastrointestinal bleed or ulcer	53100, 53101, 53110, 53130, 53131, 53140, 53141, 53150, 53151, 53160, 53170, 53190, 53191, 53200, 53201, 53210, 53211, 53220, 53221, 53230, 53231, 53240, 53241, 53250, 53251, 53260, 53270, 53271, 53290, 53291, 53300, 53310, 53330, 53340, 53350, 53360, 53370, 53390, 53391, 53501, 53511, 53541, 53551, 53561		
	Radiation toxicity	9092, 990, E8792		

(continued on next page)

Abbreviation: HCPCS, Healthcare Common Procedure Coding System.

eTable 1. ICD-9 and HCPCS Codes Utilized for Diagnosis and Treatment (cont.)				
Medicare Variable		ICD-9 Diagnosis Code	ICD-9 Procedure Code	HCPCS Codes
Nonlocal complications	Thromboembolic events	4532, 4533, 45340, 45341, 45342, 45350, 45351, 45352, 4536, 45371, 45372, 45373, 45375, 45376, 45377, 45379, 45381, 45382, 45383, 45384, 45385, 45386, 45387, 45389, 4539		
	Cytopenia	2800, 2809, 28411, 28412, 28419, 2851, 28522, 28529, 2853, 2858, 2859, 2875, 28800, 28809		
	Dehydration	27650, 27651, 27652		
	Nausea/Vomiting/Motility problem	5362, 5363, 53640, 53641, 53642, 53649, 5368, 5372, 5373, 5374, 53789, 5581, 5601, 56039, 56081, 56089, 5609, 5643, 78701, 78702, 78703, 78791		
	Malnutrition and cachexia	260, 261, 262, 2630, 2631, 2638, 2639, 7830, 78321, 7837, 7994		
	Ascites	78951, 78959		
	Pathologic fracture	73310, 73311, 73312, 73313, 73314, 73315, 73316, 73319		
	Chemotherapy-related toxicity	E9331		

Abbreviation: HCPCS, Healthcare Common Procedure Coding System.

eTable 2. Twelve-Month Cumulative Incidence of Local and Nonlocal Complications Requiring Hospitalization, Stratified by Radiotherapy or Chemotherapy^a

Local Complication	Radiotherapy	12-Month Cumulative Incidence, %			
		All Patients (N=21,500)	Resectable (N=3,092)	Unresectable (N=7,110)	Metastatic (N=11,298)
Biliary disorder	Yes	37.0	31.9	43.9	29.4
	No	29.0	27.6	43.0	22.1
Upper gastrointestinal ulcer/bleed	Yes	9.9	5.9	12.9	9.4
	No	4.7	3.1	6.2	4.3
Pain	Yes	7.4	5.4	7.8	9.5
	No	5.7	5.9	4.9	6.0
Pancreas-related	Yes	12.9	14.4	13.1	9.9
	No	11.9	14.1	15.7	8.1
Radiation toxicity	Yes	1.1	1.2	1.2	0.8
	No	0	0	0	0
Local composite	Yes	49.1	41.6	56.3	44.9
	No	39.2	38.0	52.0	32.9
Nonlocal Complication	Chemotherapy				
DVT/PE	Yes	8.9	6.1	7.0	11.4
	No	5.0	4.0	3.2	6.2
Cytopenia	Yes	35.0	28.4	39.6	35.1
	No	26.7	21.7	28.6	26.3
Dehydration	Yes	16.0	14.5	17.0	16.1
	No	11.7	11.6	12.1	11.5
Nausea/Vomiting/Motility problem	Yes	24.8	21.8	28.5	23.9
	No	18.0	19.2	19.6	16.7
Malnutrition and cachexia	Yes	23.8	19.6	26.4	23.9
	No	22.5	21.9	23.6	21.9
Ascites	Yes	6.6	4.5	6.0	7.9
	No	5.4	3.1	3.3	7.1
Pathologic fracture	Yes	0.9	0.6	0.7	1.0
	No	0.8	0.7	0.4	1.1
Chemotherapy-related toxicity	Yes	1.4	1.1	1.5	1.5
	No	0	0	0	0
Nonlocal composite	Yes	57.9	43.3	62.0	61.8
	No	52.8	42.0	53.5	54.2

Abbreviation: DVT/PE, deep vein thrombosis/pulmonary embolism.

^aEach patient may have presented with >1 symptom.